Background -Polymerized allergoids coupled to nonoxidized mannan (PM-allergoids) are novel allergen preparations used for immunotherapy.
Introduction
Canine atopic dermatitis (cAD) is a common skin condition, and allergen-specific immunotherapy (ASIT) has been used to manage it. 1, 2 Immunotherapy usually involves the subcutaneous injections of native allergen extracts administered in sequentially increasing amounts. 3 Immunotherapy using novel allergen agents has been reported in humans and dogs, including glutaraldehyde-polymerized allergoids conjugated with mannan (PM-allergoids). PM-allergoids target dendritic cells and enhance allergen uptake through C-type lectin receptors, and may induce tolerance in humans and dogs. [4] [5] [6] This study was an uncontrolled clinical small pilot trial using PM-allergoids for ASIT for cAD.
Methods and materials
This was a pilot study conducted over a 10 month period. It was approved by the Ethics Committee of the Universidad Complutense de Madrid. Sixteen dogs (10 male dogs and six female dogs; median age 3 years, range 1-7 years) of different breeds were included. Their atopic dermatitis was diagnosed on the basis of history, clinical signs and exclusion of pruritic skin conditions. 7 Food allergy was ruled out using an elimination diet for at least eight weeks. 8 Dogs had to fulfil the following criteria: a minimum score of five published diagnostic criteria, 7 a positive commercial allergen-specific IgE test (Alergovet; Madrid, Spain) and a minimum pruritus score of 5 using a 0 to 10 visual scale as evaluated by the owner. 9 All dogs were test positive to Dermatophagoides farinae and 12 dogs, in addition, were test positive to Acarus siro and/or Lepidoglyphus destructor. PM-allergoids derived from D. farinae allergens (Inmunotek, SL; Alcal a de Henares, Madrid, Spain) were used. After polymerization and conjugation with mannan, mass spectrometry analysis was performed to confirm the presence of the sequences of major house dust mite allergens in humans (Der f 1, Der f 2) and dogs (Der f 15, Der f 18).
10 PM-allergoids in sterile vials at a protein concentration of 20 lg/mL were used for immunotherapy. The treatment schedule was Day 1, 0.2 mL of PM-allergoid extract administered by subcutaneous (s.c.) injection, followed by 0.5 mL s. A pruritus Visual Analog Scale (pVAS) was used to evaluate the outcome. 9 The owners marked the scale with a cross to estimate the level of pruritus once a month prior to each immunotherapy injection. With regard to interpreting the pVAS, the maximum score (top of 100 mm scale) was attributed a value of 1 and the minimum (lower end) a value of 0. Medications including methylprednisolone (maximum dose 1 mg/ kg); ciclosporin (maximum dose 5 mg/kg) or oclacitinib (maximum dose 0.5 mg/kg) were permitted during immunotherapy. In order to calculate the medication scores (MM) and normalize the data, 1 mg of corticosteroid, 5 mg of ciclosporin and 0.5 mg of oclacitinib (all per kg) were considered equivalent, 2 adjusting the maximum value to one. At the end of the 10 month study period, the owner and a veterinarian evaluated the outcome of immunotherapy according to the following empirical and unvalidated criteria: (i) excellent: no clinical signs and no medication required; (ii) good: improvement in clinical signs with occasional supportive medication required; (iii) moderate: improvement in clinical signs, but continuous medication required with a dose reduction of at least 50%; and (iv) poor: no improvement. All adverse effects related to immunotherapy were recorded.
An Excel spreadsheet (Microsoft; Richmond, VA, USA) with the XlStat AddIn (Addinsoft; Paris, France) was used for statistical analysis. Descriptive statistics of the age and clinical signs/medication scores were expressed as a median with the first and third quartiles (IQ range). Friedman's test was used for repeated measures of the pVAS and medication scores. The post hoc Nemenyi procedure was used for pairwise comparisons.
Results
The median value of the pVAS of affected dogs prior to immunotherapy was 0.6 (range 0.6 to 0.7). The median value of the PVAS after dogs had received five immunotherapy injections over three months decreased with a median value of 0.2 (range 0.1 to 0.2) and a median of 67% improvement. The overall comparison of these values and the pairwise comparisons of all pVAS values were highly significant (P < 0.0001, Friedman's test; P = 0.001, Nemenyi procedure; Table 1 ). The individual improvement for each dog over the course of the study was greater than 60%. One dog achieved 100% improvement; in six dogs, the improvement was between 75% and 100% and in five dogs, the improvement was between 60% and 70% (Table S1 ).
At the beginning of the trial, 13 dogs were receiving corticosteroid therapy; two dogs were receiving oclacitinib and one dog was receiving ciclosporin. The change in medication scores (Table 1 ) over the course of immunotherapy was highly significant (P < 0.0001, Friedman's test). The median value of the medication scores at the beginning of the study was 0.5 IQ (range 0.5 to 0.5) and decreased to 0 (IQ range range 0 to 0.11) before the third injection was administered at one month and was significant before the fourth immunotherapy injection at two months of treatment. The pairwise comparisons also were significant (P = 0.0013, Nemenyi procedure).
The owner and treating veterinarian concurred in their evaluation of the immunotherapy with seven dogs and nine dogs achieving an "excellent" and "good" rating, respectively. One dog (Case 3) had a mild increase in pruritus after the second and third immunotherapy injections, which resolved spontaneously within an hour without intervention.
Discussion
This study reports the outcome of immunotherapy in a small number of dogs with cAD using a novel preparation of PM-allergoids for ASIT. The PM-allergoids were supplied at a single concentration and the maximum immunotherapy dose was administered in the second injection and after only one week. The dosing protocol may provide an advantage over native allergen extracts which generally require long periods of administration to reach a therapeutic (maximum) dose. 6 Owner evaluation of clinical benefit (pVAS) was obtained after two months of treatment with PM-allergoids and the median improvement in pVAS was approximately 65% after four injections and increased to 83% (75-100%) by the end of the study. Although the numbers of dogs treated in this study was very small, these results are encouraging when compared with those described for a prospective study using conventional ASIT, where the baseline clinical signs and medication scores were significantly reduced in 74% of dogs at 12 months, with 63% of cases having greater than a 50% reduction in pruritus.
11
Conventional ASIT often requires a long period of time to achieve efficacy and the use of anti-inflammatory drugs for several months. 2 In this study, using PM-allergoids for immunotherapy, drug administration was significantly reduced after one month of treatment, suggesting a more rapid clinical benefit.
This pilot study has significant and major limitations including the small number of dogs treated and the lack of a control group. Nevertheless, the novel allergen preparation containing PM-allergoids may be a useful alternative to conventional native allergen immunotherapy in atopic dogs. Larger prospective, double-blinded, placebo-controlled clinical trials are indicated.
Supporting Information
Additional Supporting Information may be found in the online version of this article. Table S1 . Changes in owner recorded pruritus scores (pVAS) for 16 dogs receiving immunotherapy based on PM-allergoids over a 10 month period.
R esum e Contexte -Les PM-allergo€ ıdes (allergo€ ıdes polym eris es coupl es au mannan nonoxidis e) sont des nouvelles pr eparations d'allerg enes utilis es en immunoth erapie. Objectif -Evaluer les PM-allergo€ ıdes comme immunoth erapie alternative chez le chien atopique (cAD) associ e a des r eponses s erologiques aux allerg enes de Dermatophagoides farinae. 
Resumen
Introducci on -los alergoides polimerizados unidos a manano no oxidado (alergoides-PM) son nuevas preparaciones de al ergenos utilizados para la inmunoterapia. Objetivo -evaluar los alergoides-PM como una inmunoterapia alternativa para perros con dermatitis at opica canina (cAD) asociados con respuestas serol ogicas a alergenos de Dermatophagoides farinae. Animales -diecis eis perros con antecedentes y signos cl ınicos de cAD; positivo en la prueba serol ogica de IgE espec ıfica del alergeno a D. farinae (cuatro perros) o Acarus siro y/o Lepidoglyphus destructor (12 perros). M etodos y materiales -un estudio piloto prospectivo sin grupo de control. Los alergoides-PM se administraron por inyecci on subcut anea durante un per ıodo de 10 meses. Se evalu o una escala visual an aloga de prurito (pVAS) y los valores de medicaci on. Se registraron las reacciones adversas. Resultados -La mediana de valor de pVAS de los perros disminuy o de 0,6 a 0,2 con una mediana del 67% de mejor ıa durante los primeros tres meses (P <0,0001). La mejora individual para cada perro fue mayor al 60%. No se observaron efectos adversos importantes.
